Age Care Labs raises ₹85 crore in Series B1 round

IMT News Desk
IMT News Desk
· 2 min read
Age Care Labs raises ₹85 crore in Series B1 as Shrem Group comes on board as strategic investor and partner to launch Shremoha premium senior living.

Age Care Labs, India’s most comprehensive elder care platform operating through its brands Emoha and Epoch Elder Care, has raised ₹85 crore (USD 9 million) in its Series B1 funding round. The Series B1 is part of a larger Series B round of INR 250 crore (USD 30 million), expected to be launched in the first quarter of 2027. The round saw participation from Rainmatter (Zerodha), Pegasus Finvest and several other prominent family offices, alongside Shrem Group.

The fresh capital will be used to strengthen Age Care Labs’ integrated elder care platform, expand its service offering, invest in technology, strengthen healthcare capabilities and accelerate its next phase of growth across India.

Alongside its strategic investment, Shrem will also partner with Emoha to establish Shremoha, a premium senior independent living platform designed for India’s rapidly growing senior population.

The partnership brings together Shrem Group’s expertise across real estate, hospitality, infrastructure and long-term capital with Emoha’s operational experience and geriatric depth in elder care. Together, the two organisations aim to build integrated senior living communities that combine independent living, wellness, hospitality and access to professional care under one platform.

Shremoha will develop premium senior independent living communities designed around the needs of modern seniors, combining thoughtfully designed residences with hospitality-led services, preventive healthcare, wellness programmes, emergency response, community engagement and coordinated care.

Saumyajit Roy, Co-founder and CEO, Emoha, said, “Through Emoha and Epoch, we have built experience across the senior care continuum, from care at home to assisted living and specialised care. Shremoha allows us to bring that capability into senior independent living, together with a partner that understands real estate, hospitality, and long-term platform creation. Our ambition is to build communities where seniors are not just cared for but are active, connected, and fully alive.”

Nitan Chhatwal, Founder and Managing Director, Shrem Group, said, “India is at the beginning of a major shift in how seniors live. The next generation of seniors is independent, aspirational, and focused on quality of life. Shremoha is being built for this shift. By bringing together Shrem’s real estate, hospitality, infrastructure, and long-term capital capabilities with Emoha’s senior care expertise, we believe we can create a category-defining senior independent living platform for India.”

Cap Connect acted as the exclusive financial advisor on the Series B1 round and the strategic partnership.

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk